Published in final edited form as:

Prim Care. 2011 March ; 38(1): 41–58. doi:10.1016/j.pop.2010.11.004.

Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy

Daniel Ciccarone, MD, MPH[Associate Professor]

Co-Director, Foundations of Patient Care, Department of Family and Community Medicine,
University of California San Francisco

Keywords

Stimulants; cocaine; amphetamine; methamphetamine

Stimulant use and abuse: a primary care issue

Recent history

Stimulants, including cocaine and amphetamines, are among the most widely used and abused illegal substances in the United States. Coca chewing has a long history of indigenous use in South America ¹. Widespread use of cocaine followed its isolation from coca in 1859 and a medical publication purporting its benefits in 1884. Its subsequent incorporation into patent medicines and popular beverages, e.g., Vin Mariani and Coca-Cola contributed to its profligate use ². Rising social and medical problems raised concern in many circles and restrictions were gradually applied until the Harrison Act (1914) banned all OTC inclusion of cocaine ³. In the US, a popularity wave of cocaine began in the 1970's followed by the crack wave of the 1980's ⁴. These waves have left paths of adverse consequences, including association with the HIV epidemic, in the latter decades of the 20th century.

The first of the synthetic stimulants, amphetamine (isolated in 1887), was first popularized in the 1930's with an OTC nasal decongestant (Bezedrine inhaler) containing the amphetamine phenylisopropylamine and the following the discoveries of clinical applications for fatigue, narcolepsy and depression ⁵. High availability, and popularity, led to misuse and OTC use was banned in 1957. Prescription misuse followed WWII (with common military usage) and illicit diversion of medications. Methamphetamine (isolated in 1919) use peaked during the late 1960's creating a "speed scene." The passage of the Controlled Substances Act in 1971 led to a dramatic decline in prescribed amphetamine and the popularity of amphetamines and methamphetamine declined for a time ⁶. The 1990's brought a reemergence of methamphetamine, particularly to the western US, concurrent to mounting small scale production, aka "meth labs," first in California and subsequently spreading nationwide ⁷. New forms of methamphetamine, e.g., "crank" and "ice," have had

© 2010 Elsevier Inc. All rights reserved.

Correspondance: **Dan Ciccarone MD, MPH**, Associate Professor, Co-Director, Foundations of Patient Care, Department of Family and Community Medicine, 500 Parnassus, MU-3E, Box 0900, University of California, San Francisco, CA 94143, 415-514-0275 (VM), 415-476-6051 (Fax), ciccaron@fcm.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

their popularity waves as well. The popularity of amphetamines is reciprocal with cultural representations throughout the 1940's – 1990's, e.g., in literature, movies and music 8· 9.

Epidemiology

According to the National Survey on Drug Use and Health (NSDUH), the national prevalence of current cocaine use is third after marijuana and misuse of prescription medications. The estimated lifetime prevalence of cocaine use is 14.7% of the US population 12 years of age or older (3.4%, crack use prevalence). Current use (past month) of cocaine was reported by 0.7% of persons aged 12 and older in 2008, decreasing significantly from 1.0% in 2003. The proportion reporting current crack use, 0.1%, also decreased from 2003 levels (0.3%) ¹⁰. The NSDUH may underreport drug use in certain populations, including the homeless, institutionalized persons and college students.

The estimated lifetime prevalence of non-medical amphetamine use is 8.5% of the US population according to the NSDUH 2008, down from 9.7% in 2003. Current use of all amphetamines is reported at 0.4% (2008) down from 0.6% (2003); only 0.1% of the population reports current methamphetamine use in the latest survey; this is decreased from 0.3%. Methamphetamine use is more prevalent in the western US, but is trending eastward ¹¹.

The Drug Abuse Warning Network (DAWN) is a national survey of non-federal short-stay hospitals with 24 hour emergency departments (ED) of patient visits associated with drug misuse or abuse; DAWN has a separate survey of medical examiner data on mortality related to illegal drug use. According to the 2006 DAWN survey, one in three (31%) of all drug-related emergency visits involved cocaine; methamphetamine was associated with 5% of all ED visits and amphetamine, 2%. No statistically significant change in stimulant-related ED mentions was noted over the past two annual surveys ¹². In the DAWN mortality state profiles, cocaine was one of the top 3 drugs involved in drug-related deaths in six of ten states; stimulants (amphetamines and methamphetamine) ranked in the top 10, of mortality involved drugs, in six of ten states; with four being western states ¹³. While household surveys report low methamphetamine use prevalence, regional law enforcement agencies are reporting heightened concerns. In addition, the associated economic and societal costs of methamphetamine use are estimated to be high ¹⁴.

Forms, preparation and use

Cocaine

Cocaine is a naturally occurring alkaloid in the leaves of the coca plant, *Erythroxylon coca*, which is indigenous to the Andean region of South America. The area of coca under cultivation in Colombia, Peru and Bolivia peaked in 2000 at 221,300 hectares, subsequently declining to 167,600 hectares in 2008. Most of the cocaine derived from this harvest is for export. Estimates of potential cocaine production for the region have varied little since 1994: in that year estimated production was 891 metric tons; since peaking in 2000 at 1008 metric tons there has been a decline to 845 metric tons in 2008. Global cocaine seizures have risen dramatically in the last decade: in 2007, 711 metric tons of street-level cocaine were seized, double the amount in 2000. Adjusting for purity, an estimated 42% of global pure cocaine was reportedly confiscated in 2007 ¹⁵.

Cocaine is street-available in both acidic (salt) and basic forms ¹⁶. Cocaine hydrochloride (aka, "coke," "blow," "snow," "nose candy," "yayo") ¹⁷ is a water soluble powder with a high melting point. As such it is bioavailable (~30–60%) through insufflation (i.e., snorting, or "tooting"), or easily dissolved for intravenous injection; it is not usually smoked as the active ingredient is destroyed by the temperatures required for vaporization. Time to peak

subjective effect averages 14.6 minutes after insufflation compared to 3.1 minutes following injection 18. Nasal absorption is limited due to the vasoconstrictive properties of cocaine.

Base cocaine, aka “crack,” or “rock” 17, can be vaporized and inhaled due it is lower melting point. The term “crack” reportedly comes from the sound the material makes while melting ⁶. Since its entry into the US market in 1985, crack cocaine rapidly spread due to its low cost and rapid action. The time to reach peak subjective effect is significantly faster for smoked (1.4 min) than for intravenous or insufflated cocaine ¹⁸. In the 1980’s street-doses were frequently seen in US cities selling for as little as \$2.50–5.00 ¹⁹. Crack cocaine largely replaced an outmoded base form called “freebase,” which involved a complicated series of dangerous steps to solubilize and extract base cocaine from its hydrochloride salt.

The average purity of cocaine available on US streets was 50–60% in 2007 [ref: DEA cocaine 2008]. Diluents, i.e., fillers, or “cut,” include simple sugars, e.g., dextrose, starch, or white inert powders, e.g., talc. Adulterants, which may have some additive or mimicking active effects, include topical anesthetics, e.g., procaine, and cheaper stimulants, e.g., caffeine or ephedrine ²⁰. Reports of adverse consequences from levamisole (a veterinary medication) tainted cocaine have risen recently ²¹. Cocaine is frequently used by heroin dependent users in combination, aka, “speedball.” Tobacco, alcohol and marijuana are frequently used in conjunction with cocaine.

Amphetamine – methamphetamine

Historically, US illicit methamphetamine came from small producers in Mexico and California. The 1990’s saw growth and spread in the domestic production of methamphetamine. DEA domestic methamphetamine seizures rose dramatically from 272 kilograms (kgs) in 1990 to 1,549 kgs in 2008 after peaking at 2,161 kgs in 2005 ²³. The number of US methamphetamine laboratory seizures increased from 7,025 in 2000 to 10,249 in 2003, declining to 2,584 in 2008 ²⁴. Much of this decline has been offset by increased importation of methamphetamine from Mexico. Methamphetamine can be made from OTC nasal decongestant products containing ephedrine and pseudoephedrine. For this reason, strict controls have been placed on OTC purchases and well as other precursor supplies. Since 2004, 44 states have restricted sales ²⁵. Since 2005, the government of Mexico has progressively increased precursor controls with some measurable effect on production ²⁴.

Methamphetamine exists in two stereoisomer, i.e., *l*- and *d*-, forms. *l*-methamphetamine has peripheral alpha-adrenergic activity and has been used in the past as a nasal decongestant (i.e., Vicks inhaler). *D*-methamphetamine (aka “speed,” “crystal,” “meth,” or “crank”) is a powerful stimulant with 3–5 times the CNS activity as the *l*-isomer and a half-life of 10–12 hours (cocaine’s half life is 0.5–2 hours) ²⁶. It can be insufflated, smoked, injected, or inserted per rectum. Its forms are powder (usually white, but may be of other colors), or crystalline. “Ice” (aka “glass,” or “Tina”) is a highly purified form of *d*-methamphetamine which is intended for smoking; it vaporizes at an even lower temperature than crack cocaine ^{27, 28}.

Amphetamines – other

Several synthetic stimulants, including amphetamine and methylphenidate, are available as prescription drugs. Forms include tablets, capsules, liquids and patches. Indications include attention deficit and hyperactivity disorder (ADHD), weight control and narcolepsy. OTC stimulants include aerosolized or ingested forms of decongestants as well as caffeine in multifarious forms ²⁹. There has been a recent boom of highly caffeinated beverages, aka, “energy” drinks ³⁰.

Diversion of prescription stimulants is a concern. Given the increase in diagnosis of ADHD, the number of prescriptions for stimulant medication has grown. Surveys of college students reveal that illicit use of stimulants has grown recently and is at its highest level in decades³¹. However, there is no evidence that appropriate medical use of prescription stimulant medication leads to increased drug abuse. While studies examining cohorts of persons with ADHD confirm high prevalences of adult comorbid substance use disorders, they also find that treatment with stimulant medication is not associated with increased substance abuse in adulthood³².

OTC stimulant-based appetite suppressants have also raised concern over the past two decades. Fenfluramine-phentermine (aka Fen-phen) was a combination stimulant medication widely advertised and popular in the 1990's. Its adverse association with cardiac valvular regurgitation and pulmonary hypertension led to its removal from the market in 1997³³. An OTC decongestant and appetite suppressant, phenylpropanolamine, was removed from the market in 2005 after an association with hemorrhagic stroke among women was found³⁴.

Effects on Neurotransmitter Systems

Stimulants facilitate the activity of the monoamine neurotransmitters, i.e., dopamine, norepinephrine and serotonin, in the central (CNS) and peripheral nervous systems^{35, 36}. Both cocaine and amphetamines act on presynaptic monoamine reuptake transporters, but each in unique ways. Cocaine is a reuptake inhibitor, i.e., it blocks the action of the reuptake transporter thus allowing more neurotransmitter to stay active in the synapse. Amphetamines are releasers, i.e., they are taken up by the transporter in exchange for neurotransmitter release into the synapse.

The reward circuit of the CNS includes dopamine pathways extending from the ventral tegmental area (VTA) of the midbrain to the pre-frontal cortex and limbic regions, including the shell of the nucleus accumbens and ventral pallidum; with the key areas for stimulant reward being the pre-frontal cortex and nucleus accumbens. Animal and human studies support the role of dopaminergic activity, particularly in these pathways, as mediating the behavioral effects of stimulants³⁶. Cocaine and amphetamine intake transiently increases extracellular dopamine concentrations in the reward circuit³⁷. Affinity for the dopamine transporter is correlated to behavioral reinforcing effects in animal studies of varying stimulant potencies³⁸. Genetically engineered mice with dopamine transporters altered to not bind cocaine show no reinforcing effects of cocaine administration³⁹. Likewise, knockout mice lacking dopamine D₁ receptors do not self-administer cocaine⁴⁰. In human PET imaging studies, increases in dorsal striatum dopamine are associated with self-reported euphoric responses to acute stimulant use, as well as to conditioned drug cues³⁷. Blockade of more than half the dopamine transporters is required to reduce the psychological or behavioral effects of stimulants⁴¹. Thus, studies of dopamine receptor antagonists (e.g., antipsychotic medications) or synthesis inhibitors usually fail due to intolerance to the experimental drugs' effects⁴².

Stimulants also increase serotonin and norepinephrine activity and have effects on a number of other neurotransmitter systems. Serotonin enhancement is contributory, but not obligatory, in the behavioral rewarding from stimulant use⁴³. The subjective effects of stimulants of varying potencies are correlated with norepinephrine release⁴⁴. Glutamate may play an important role in relapse to cocaine or amphetamine abuse⁴⁵. Environmental cues and drug seeking leading to glutamatergic upregulation is a proposed model. Stimulants also increase acetylcholine release in the brain and may play a role in reward pathways⁴⁶.

Clinical features

Acute use: intoxication and overdose

The clinical effects of stimulant use, including psychological, behavioral and physiological effects, vary by acute versus chronic use, potency of drug, route of administration and dosage.

Acutely, use of stimulants leads to rapid neurotransmitter release resulting in euphoria, increased energy and libido, reduced fatigue and appetite, and behavioral responses, e.g., increased self-confidence and alertness⁴⁷. Acute adrenergic effects include dose-responsive tachycardia and elevated blood pressure. Dose-equivalent responses to cocaine are seen with approximately 15–25 mg injected intravenously or smoked, 40–100 mg insufflated, or 100–200 mg ingested; oral amphetamine is approximately 10 times more potent per mg⁴⁸.

With escalating effective dose (i.e., by greater potency, amount or more efficient route) there is greater euphoria at first, but also increased likelihood of toxic and dysphoric effects including: insomnia, anxiety, irritability, confusion, paranoia, panic attacks and hallucinations; related behavioral consequences include impulsivity and grandiosity^{49, 50}. Acute adrenergic side-effects include hyperpyrexia, hyperreflexia, tremor, diaphoresis, tachycardia, hypertension and tachypnea⁵¹. Overdose may manifest in convulsions, cerebral hemorrhage or infarct, cardiac arrhythmias or ischemia, respiratory failure and muscle overactivity leading to rhabdomyolysis⁵².

Chronic use

Chronic use of stimulants is frequently carried out in binge-abstinence cycles. Cycles of use can last 12 or so hours (typically cocaine) to several days (methamphetamine). This is reported in epidemiological studies^{53, 54}, as well as animal studies⁵⁵.

Cyclical use, drug craving and relapse may be explained by the concept of sensitization⁵⁶. This occurs when intermittent use of a drug leads to enhanced effects; since the latter is often desired, cyclical use is learned and practiced. Repeated phasic use of low-dose cocaine may lead to increased sensitivity including startle reactions, repetitive and stereotyped behaviors, and alteration of motor function⁵⁷. There is cross-sensitization among stimulants in that prior amphetamine administration subsequent boosts the effects of cocaine⁵⁸.

Some of the most prominent and disturbing effects of escalating stimulant use include a spectrum of psychotic features including, paranoia, delusions and hallucinations⁵⁹. The latter include tactile hallucinations, or formication, colloquially referred to as “tweaking,” in which users will commonly pick at their skin, or perform other repetitive searching behaviors⁶⁰. Twenty-five to fifty percent of chronic stimulant users report experiencing psychotic symptoms, and sensitization may worsen these with continued use^{49, 61, 62}. Psychotic symptoms may also persist for years following abstinence from amphetamine use⁶³, with flashbacks reported by methamphetamine users up to 2 years following last use⁶⁴.

In time, neurotransmitter downregulation can occur, leading to an array of clinical features. Tolerance to the psychological and physical effects of stimulants may develop after several doses or within weeks^{48, 65}. Imaging studies reveal decreased dopamine release and receptor availability in chronic users³⁷. Changes in brain structure, e.g., decreased frontal cortex volume and enlarged basal ganglia, are also associated with chronic cocaine use⁶⁶. Cognitive impairment may result and persist for months following abstinence⁶⁷.

Withdrawal from cocaine and amphetamine produces such a strong backlash of psychological and behavioral symptoms that it is frequently referred to as a “crash.” Acute

withdrawal symptoms include hypersomnolence, strong cravings and depression. Following this may be a several week period of dysphoria, lethargy and anhedonia^{68, 69}. Relapses are common due to environmental cueing and the stark contrast between “high” and “crash” states.

Addiction

The potential for misuse, dependence and abuse of stimulants is high. Surveys of persons not in treatment estimate that 10–15% of stimulant users will become dependent⁷⁰; in treatment seeking populations the proportion exceeds 50%⁷¹. Heavier use is clearly related to dependency, but route of use is also a key factor; stimulant smokers and injectors are more likely to become dependent⁷². Faster pharmacokinetics (e.g., smoked over ingested routes) and shorter peak to trough cycles (e.g., cocaine over methamphetamine) aid abuse potential⁷³.

The American Psychiatric Association Diagnostic and Statistical Manual (DSM-IV, Text Revision) requires several criteria be met for the diagnosis of stimulant abuse. The criteria include evidence of a maladaptive pattern of use, clinically significant impairment and more than one of the following (in a 12 month period): 1) failure to fulfill major role obligations; 2) use in physically hazardous situations; 3) recurrent legal problems; and 4) continued use despite social and interpersonal problems⁷⁴.

The variability seen individuals’ responses to stimulants may be due to genetics, personality traits, or social/environmental cues (e.g., drug use setting), as well as a variety of other factors. The role of genetics is supported by twin studies, in which identical twins are highly concordant in the response to acute stimulant intake, initiation of stimulants and on stimulant dependence and abuse⁷⁵.

Medical complications

The medical consequences of stimulant abuse are many and occur in all major organ systems (Table 1). One way of understanding and categorizing these problems is by mechanism of injury, e.g., ischemia, nervous system stimulation, direct toxicity and other.

Mechanisms leading to tissue ischemia include vasoconstriction, vasospasm, endothelial damage and clotting stimulation (e.g., increased platelet activation and aggregation)⁷⁶. Stimulant use is associated with cerebrovascular disease and injury, including hemorrhagic and ischemic stroke⁵¹; myocardial infarction (all aforementioned reasons plus increased oxygen demand)⁷⁷; renal failure (secondary to ischemia or rhabdomyolysis)⁷⁸, gastrointestinal disease (e.g., ulceration and intestinal infarction)^{76, 79}; muscle damage (also possible direct toxicity; leading to rhabdomyolysis, with up to one-third of patients developing acute renal failure)^{76, 80}; nasal and sinus damage⁸¹; and reproductive complications (e.g., abruption placenta, low birth weight and feeding difficulties; concerns persist regarding infant cognitive deficits, but longer-term studies are somewhat reassuring)^{82–84}.

Excess nervous system stimulation secondary to stimulant use is associated with: seizures (usually tonic-clonic)^{76, 85}; movement disorders (increased basal ganglia dopaminergic activity resulting in repetitive behaviors, aka “tweaking,” acute dystonic reactions, dyskinesia and akathisia, etc)^{48, 86}; and psychotic symptoms^{63, 87} (both through dopaminergic excess⁸⁸ and focal perfusion deficits (methamphetamine)⁸⁹). Sympathetic nervous system stimulation leads to tachycardia and elevated blood pressure⁵¹; endocrine stimulation or inhibition (e.g., dopamine inhibition of pituitary prolactin)⁹⁰; and sexual dysfunction⁹¹.

Stimulant use may cause direct tissue toxicities resulting in associations with: cardiac arrhythmias (secondary to sodium channel blockade and increased norepinephrine) 92, 93; myocarditis and cardiomyopathy (toxic effect of drug or from chronic exposure to high levels of catecholamines) 92, 94; and pulmonary symptoms and disease (from acute shortness of breath to pulmonary edema; presumably due to combination of direct toxicity and vascular changes) 95, 96.

The pathophysiology of many of these adverse organ events is incompletely understood, and many have overlapping etiologies. In addition, some may be due to, or exacerbated by, drug contamination, or secondary to lifestyle (e.g., malnutrition) and social/environmental factors. A good example is “meth mouth,” dental and periodontal decay due to a combination of tissue shrinkage, poor fluid and high sugar intake, and neglect 97.

HIV

Use of stimulants is associated with HIV through drug and sexual risk taking, as well as through social mechanisms, e.g., poverty and sexual power dynamics. Drug injection is a well known risk with transmission increased by syringe/needle and paraphernalia sharing 98. Cocaine use is associated with increased frequency of injection and needle sharing 99. Injection risk behaviors also increase transmission risk for other viruses including HCV and HBV; HCV has a particularly high incidence among injection drug users 100.

Sexual risk (including risk taking and imposed social/power risk) is also increased among cocaine users with reported increased numbers of partners, increased frequency of unprotected intercourse, and exchange of sex for money or drugs 101. Use of crack cocaine was independently associated with HIV in a large epidemiological study; transmission is likely through the confluence of poverty and sexual risk 102.

Use of methamphetamine is also associated with sexual risk taking leading to HIV and other sexually transmitted diseases (STDs) in both heterosexual and men-who-have-sex-with-men (MSM) populations 103. Urban MSM have a much higher prevalence of methamphetamine use than that in the general population 104. In MSM cohort studies, methamphetamine use is associated with unprotected anal intercourse 105, 106. In a cross-sectional study of MSM, methamphetamine use concurrent with unprotected anal intercourse was an independent risk factor for recent HIV seroconversion 107. The use of erectile dysfunction (ED) medications, e.g., Viagra (sildenafil citrate), in the “party and play” scene is creating concern 103. The combination of ED medication (or amyl/butyl nitrate, aka “poppers”) and methamphetamine is considered a sexual performance duo; the erectile dysfunction drug counters one of the common consequences of methamphetamine use 108. This combination unfortunately leads to increased sexual risk taking 109, STDs 110 and HIV seroconversion 111.

Treatment

Screening

In the primary care setting, substance use concerns lie in a continuum of risk and many patients with low- to moderate substance use disorders present sub-clinically. Screening for at-risk levels of alcohol use in the primary care setting has been given a B rating (recommended based on fair evidence) by the US Preventive Services Task Force (USPSTF) 112. However, according to the USPSTF, the benefit and clinical utility of screening asymptomatic patients for illicit substance use remains unclear 112. Other professional groups, e.g., American Academy of Pediatrics, recommend identification of adolescents at risk for substance use disorders 113 and the American College of Obstetrics and Gynecology recommends screening of pregnant women 114. Many validated screening instruments exist, e.g., CAGE-AID (CAGE Adapted to Include Drugs), Alcohol Use

Disorders Identification Test (AUDIT; including adaptations for illicit drug screening) and Drug Abuse Screening Test (DAST). Given time and resource constraints, a consensus panel has recommended a single screening question: “Have you used street drugs more than five times in your life?”¹¹⁵ Another single screening question has been recently tested for use in primary care settings (Dr. R. Saitz as cited in: Zgierska, 2009) 116: “How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?”

Screening, brief interventions and referral to treatment (SBIRT) is a clinical model with a growing evidence base. Brief intervention, focusing on risk reduction, involves client-centered counseling sessions assessing motivation to change, reflection on the personal consequences of drug use and setting of treatment goals. The Feedback, Responsibility, Advice, Menu of treatment options, Empathic and Self-Efficacy (FRAMES) model utilizing motivational interviewing is a key technique¹¹⁷. The evidence for the effectiveness of screening and brief interventions is extensive for reducing risky alcohol use^{118–120} and evolving for addressing substance misuse. An evaluation of a large multisite Federally funded SBIRT service program found significant reductions in the proportion of patients using illicit drugs – including cocaine and methamphetamine – at 6-month follow-up¹²¹. Additional studies support brief motivational intervention in reducing cocaine¹²² and amphetamine use¹²³. The adoption of 2008 Medicare and Medicaid billing codes should facilitate dissemination of SBIRT in primary care settings¹¹⁶.

Behavioral/Social

Behavioral and psychosocial approaches are the mainstays of treatment for stimulant dependence, while pharmacological treatment remains elusive (see section below)¹²⁴. These approaches include cognitive behavioral therapy, community reinforcement approach, contingency management, as well as combinations of these and other approaches. A meta-analysis of psychosocial treatments for cocaine abuse found a statistically borderline, but moderate reduction in combined dependency outcomes¹²⁵. Cognitive behavioral therapy focuses on learning strategies to change maladaptive patterns and increase coping skills; relapse prevention is a common goal. For cocaine dependence, use of cognitive behavioral therapy has been shown more effective than less intensive approaches^{126–128}, particularly for those with greater disease burden¹²⁹. A recent review showed the effectiveness of cognitive behavioral therapy for the treatment of methamphetamine dependence¹³⁰.

Contingency management is one of the most promising approaches for the treatment of substance use disorders, including cocaine and methamphetamine abuse. The conceptual foundation of contingency management is based in operant conditioning; the study of how systematically applied conditions effect voluntary behavior. Artificially applied conditions are designed to either reinforce or punish a set of defined behaviors (e.g., drug use) to achieve a defined behavioral goal (e.g., drug abstinence)¹³¹.

Contingency management falls on a spectrum of behavioral treatment options available in substance use treatment. Contingency management is unique in that it utilizes ‘contrived’ reinforcements to achieve the explicit goal of short-term drug abstinence. These reinforcements commonly include financial reward, or the use of vouchers for goods and services, e.g., housing. This differs from a community-reinforcement approach, which focuses on ‘natural’ social reinforcements that exist in the community, e.g., support from a social group or praise from a spouse.

The effectiveness of contingency management for substance use treatment is supported by a number of meta-analyses^{125, 132–134}. For the treatment of cocaine dependence, effectiveness of contingency management has been shown in a meta-analysis¹³³ and several

randomized control trials^{135–137}. Combining contingency management with cognitive behavioral therapy revealed no clear benefit from contingency management alone¹³⁵. A community reinforcement approach combined with vouchers looks promising¹³⁸. One persistent concern is that the effects of contingency management are short-lived, i.e., the benefits diminish once the vouchers are removed. In a study of contingency management versus cognitive behavioral therapy for stimulant dependence, contingency management was superior during the trial phase, but cognitive behavioral therapy was equivalent in effect once the trial was over¹³⁹. Contingency management combined with cognitive behavioral therapy improved abstinence among methamphetamine users¹⁴⁰. In a population of gay and bisexual men, contingency management improved methamphetamine use risk, while a culturally modified cognitive behavioral approach reduced sexual risk behavior¹⁴¹. A review of behavioral and psychosocial treatments for stimulant use found no evidence for difference in treatment efficacy between the management of cocaine and methamphetamine use¹²⁴.

Pharmacological

No medication is currently approved by the US Food and Drug Administration (FDA) for use in cocaine or amphetamine dependence. Numerous classes of medication have been studied, primarily in small clinical trials. Antidepressants, including heterocyclic, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and others have been explored and found to have no effect on cocaine abstinence¹⁴². A pooled analysis from a multisite trial of four medication classes, including antidepressants, mood stabilizers, dopamine agonists and neuroprotectives, found no significant effect on abstinence for any of the four classes¹⁴³. A combined approach of newer antidepressant medication and contingency management is showing promise^{144, 145}.

Summary

The high prevalence of use and harmful consequences makes screening, diagnosis and referral for treatment of persons with stimulant abuse a top concern for primary care providers. Having a working knowledge of use patterns, clinical symptomatology, end-organ effects and advances in treatment of stimulant abuse is essential.

While cocaine and amphetamine have different use patterns, duration of action, etc., the consequences of use are remarkably similar. Effective psychosocial treatments, e.g., contingency management, are available, while pharmaceutical treatment remains elusive. Primary care is at the forefront of screening, brief risk-reduction interventions and diagnosis of medical sequelae; with referral to addiction specialist treatment when necessary.

Acknowledgments

The author gratefully acknowledges the contributions of Nathan Sackett, RN in researching and editing sections of this manuscript.

This work was supported by Grant DA16165, from the National Institutes of Health, National Institute on Drug Abuse

References

1. Thoumi, FE. *Illegal drugs, economy, and society in the Andes*. Washington, D.C.: Woodrow Wilson Center Press; 2003.
2. Spillane, JF. *Cocaine: from medical marvel to modern menace in the United States, 1884–1920*. Baltimore: Johns Hopkins University Press; 2000.

3. Musto, DF. The American disease: origins of narcotic control. 3rd ed.. New York: Oxford University Press; 1999.
4. Reinarman, C.; Levine, HG., editors. Crack in America: demon drugs and social justice. Berkeley and Los Angeles: University of California Press; 1997.
5. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. *Journal of the History of Medicine and Allied Sciences* 2006;61(3):288–323. [PubMed: 16492800]
6. Goode, E. Drugs in American society. 6th ed.. New York: McGraw-Hill; 2005.
7. Hunt, D.; Kuck, S.; Truitt, L. Methamphetamine Use: Lessons Learned, final report to the National Institute of Justice 2006. 2006 Feb. (NCJ 209730).
8. contributors W. Benzedrine. [Accessed March 27, 2010]. Available at: <http://en.wikipedia.org/w/index.php?title=Benzedrine&oldid=351645502>
9. contributors W. Amphetamine. [Accessed March 27, 2010]. Available at: <http://en.wikipedia.org/w/index.php?title=Amphetamine&oldid=352155493>
10. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD: 2009.
11. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992–2007. *Drug Alcohol Rev* 2008 May;27(3):229–235. [PubMed: 18368603]
12. Substance Abuse and Mental Health Services Administration OoAS. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339. Rockville, MD: 2008. 2008
13. Substance Abuse and Mental Health Services Administration OoAS. Drug Abuse Warning Network, 2007: Area Profiles of Drug-Related Mortality. HHS Publication No. SMA 09-4407, DAWN Series D-31. Rockville, MD: 2009. 2009
14. Nicosia, N.; Pacula, RL.; Kilmer, B.; Lundberg, R.; J, C. The economic cost of methamphetamine use in the United States, 2005. Santa Monica: RAND Drug Policy Research Center; 2009. 2009
15. United Nations Office on Drugs and Crime. 2009 World Drug Report. Vienna: 2009.
16. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? *JAMA* 1996 Nov 20;276(19):1580–1588. [PubMed: 8918856]
17. contributors UD. Cocaine. [Accessed March 31, 2010]. Available at: <http://www.urbandictionary.com/define.php?term=cocaine>
18. Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. *Life Sciences* 2000;67(12):1507–1515. [PubMed: 10983846]
19. US Drug Enforcement Administration. "DEA History Book, 1876 – 1990" (drug usage & enforcement), US Department of Justice. [Accessed March 31, 2010]. USDoJ.gov webpage: <http://www.justice.gov/dea/pubs/history/1985-1990.html>
20. Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. *Am J Emerg Med* 1991;9:336–342. [PubMed: 2054004]
21. Kinzie E. Levamisole found in patients using cocaine. *Ann Emerg Med* 2009 Apr;53(4):546–547. [PubMed: 19303517]
22. Knowles L, Buxton JA, Skuridina N, et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. *Harm Reduct J* 2009;6:30. [PubMed: 19919709]
23. US Drug Enforcement Administration. Stats and Facts. [Accessed April 2, 2010]. <http://www.justice.gov/dea/statistics.html>
24. US Department of Justice, National Drug Intelligence Center. National Drug Threat Assessment 2009. Washington, DC: 2008.
25. US Department of Justice, National Drug Intelligence Center. National Methamphetamine Threat Assessment 2007. Washington, DC: 2006.
26. Ellenhorn, MJ.; Schonwald, S.; Ordog, G., et al. Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning. 2nd ed. ed.. Baltimore: Williams and Wilkins; 1997.

27. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. *J Addict Dis* 2002;21(1):21–34. [PubMed: 11831497]
28. Schifano F, Corkery JM, Cuffolo G. Smokable (“ice”, “crystal meth”) and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. *Ann Ist Super Sanità* 2007;43(1):110–115.
29. Masand PS, Tesar GE. Use of stimulants in the medically ill. *Psychiatr Clin North Am* 1996 Sep; 19(3):515–547. [PubMed: 8856815]
30. Warner M. A jolt of caffeine, by the can. *New York Times*. 2005 Nov 23; 2005.
31. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. *J Psychoactive Drugs* 2006 Mar;38(1):43–56. [PubMed: 16681175]
32. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? *Am J Psychiatry* 2008 May;165(5):553–555. [PubMed: 18450933]
33. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. *Am Heart J* 2002 Dec;144(6):1065–1073. [PubMed: 12486432]
34. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. *N Engl J Med* 2000 Dec 21;343(25):1826–1832. [PubMed: 11117973]
35. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. *Annu Rev Pharmacol Toxicol* 2007;47:681–698. [PubMed: 17209801]
36. Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. *Biochem Pharmacol* 2008 Jan 1;75(1):196–217. [PubMed: 17825265]
37. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. *Neuropharmacology* 2009;56 Suppl 1:3–8. [PubMed: 18617195]
38. Wee S, Carroll FI, Woolverton WL. A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. *Neuropsychopharmacology* 2006 Feb;31(2):351–362. [PubMed: 15957006]
39. Chen R, Tilley MR, Wei H, et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. *Proc Natl Acad Sci U S A* 2006 Jun 13;103(24):9333–9338. [PubMed: 16754872]
40. Caine SB, Thomsen M, Gabriel KI, et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. *J Neurosci* 2007 Nov 28;27(48):13140–13150. [PubMed: 18045908]
41. Kimmel HL, O'Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. *Pharmacol Biochem Behav* 2007 Jan;86(1):45–54. [PubMed: 17258302]
42. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. *Trends Neurosci* 1991 Jul;14(7):299–302. [PubMed: 1719677]
43. Filip M, Frankowska M, Zaniowska M, Golda A, Przegalinski E. The serotonergic system and its role in cocaine addiction. *Pharmacol Rep* 2005 Nov–Dec;57(6):685–700. [PubMed: 16382187]
44. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse* 2001 Jan;39(1):32–41. [PubMed: 11071707]
45. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. *Biochem Pharmacol* 2008 Jan 1;75(1):218–265. [PubMed: 17706608]
46. Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. *Neuropsychopharmacology* 2008 Jul;33(8):1779–1797. [PubMed: 17928814]
47. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. *Pharmacotherapy* 2006 Aug;26(8):1148–1156. [PubMed: 16863490]
48. Angrist, B., editor; Engel, J.; Orelan, L.; Ingvar, DH., et al., editors. Clinical effects of central nervous system stimulants: a selective update. New York: Raven Press; 1987. Brain reward systems and abuse
49. Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. *Drug Alcohol Depend* 1997 Jun 6;46(1–2):105–113. [PubMed: 9246558]

50. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. *J Addict Dis* 2005;24(3):115–132. [PubMed: 16186088]
51. O'Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. *Med Clin North Am* 2005 Nov;89(6):1343–1358. [PubMed: 16227066]
52. Gay GR. Clinical management of acute and chronic cocaine poisoning. *Ann Emerg Med* 1982 Oct; 11(10):562–572. [PubMed: 6751171]
53. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. *Curr HIV/AIDS Rep* 2005 Nov;2(4):194–199. [PubMed: 16343378]
54. Myers MG, Rohsenow DJ, Monti PM, Dey A. Patterns of cocaine use among individuals in substance abuse treatment. *Am J Drug Alcohol Abuse* 1995 May;21(2):223–231. [PubMed: 7639208]
55. O'Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. *Pharmacol Ther* 2005 Oct;108(1):18–58. [PubMed: 16183393]
56. Kalivas PW, Pierce RC, Cornish J, Sorg BA. A role for sensitization in craving and relapse in cocaine addiction. *J Psychopharmacol* 1998;12(1):49–53. [PubMed: 9584968]
57. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. *Addiction* 2000 Aug;95 Suppl 2:S91–S117. [PubMed: 11002906]
58. Bonate PL, Swann A, Silverman PB. Context-dependent cross-sensitization between cocaine and amphetamine. *Life Sci* 1997;60(1):PL1–PL7. [PubMed: 8995535]
59. Mahoney JJ 3rd, Kalechstein AD, De La Garza R 2nd, Newton TF. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. *Am J Addict* 2008 Mar–Apr;17(2):83–98. [PubMed: 18393050]
60. Fasano A, Barra A, Nicosia P, et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punning. *Drug Alcohol Depend* 2008 Jul 1;96(1–2):178–182. [PubMed: 18378407]
61. Hall W, Hando J, Darke S, Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. *Addiction* 1996 Jan;91(1):81–87. [PubMed: 8822016]
62. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J. Adverse effects of stimulant drugs in a community sample of drug users. *Drug Alcohol Depend* 1997 Mar 14;44(2–3):87–94. [PubMed: 9088780]
63. Flaum M, Schultz SK. When does amphetamine-induced psychosis become schizophrenia? *Am J Psychiatry* 1996 Jun;153(6):812–815. [PubMed: 8633695]
64. Yui K, Ishiguro T, Goto K, Ikemoto S. Factors affecting the development of spontaneous recurrence of methamphetamine psychosis. *Acta Psychiatr Scand* 1998 Mar;97(3):220–227. [PubMed: 9543311]
65. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. *Neuropsychopharmacology* 1998 Apr;18(4): 263–271. [PubMed: 9509494]
66. Lim KO, Wozniak JR, Mueller BA, et al. Brain macrostructural and microstructural abnormalities in cocaine dependence. *Drug Alcohol Depend* 2008 Jan 1;92(1–3):164–172. [PubMed: 17904770]
67. Yucel M, Lubman DI, Solowij N, Brewer WJ. Understanding drug addiction: a neuropsychological perspective. *Aust N Z J Psychiatry* 2007 Dec;41(12):957–968. [PubMed: 17999268]
68. Coffey SF, Dansky BS, Carrigan MH, Brady KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. *Drug Alcohol Depend* 2000 Jun 1;59(3):277–286. [PubMed: 10812287]
69. Lago JA, Kosten TR. Stimulant withdrawal. *Addiction* 1994 Nov;89(11):1477–1481. [PubMed: 7841859]
70. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. *Exp Clin Psychopharmacol* 1994;2:244–268.
71. Woody GE, Cottler LB, Cacciola J. Severity of dependence: data from the DSM-IV field trials. *Addiction* 1993 Nov;88(11):1573–1579. [PubMed: 8287004]

72. Gossop M, Griffiths P, Powis B, Strang J. Cocaine: patterns of use, route of administration, and severity of dependence. *Br J Psychiatry* 1994 May;164(5):660–664. [PubMed: 7921717]
73. Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. *Adv Pharmacol* 1998;42:995–997. [PubMed: 9328065]
74. Association AP. *Diagnostic and Statistical Manual of Mental Disorders*. Fourth Edition, Text Revision ed.. Washington, DC: American Psychiatric Association; 2000.
75. Agrawal A, Lynskey MT. Are there genetic influences on addiction: evidence from family, adoption and twin studies. *Addiction* 2008 Jul;103(7):1069–1081. [PubMed: 18494843]
76. Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. *Heart Lung* 1997 Nov–Dec;26(6):466–483. quiz 484–465. [PubMed: 9431493]
77. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. *Circulation* 2001 Jan 30;103(4):502–506. [PubMed: 11157713]
78. Gitman MD, Singhal PC. Cocaine-induced renal disease. *Expert Opin Drug Saf* 2004 Sep;3(5):441–448. [PubMed: 15335299]
79. Glauser J, Queen JR. An overview of non-cardiac cocaine toxicity. *J Emerg Med* 2007 Feb;32(2):181–186. [PubMed: 17307630]
80. Doctora JS, Williams CW, Bennett CR, Howlett BK. Rhabdomyolysis in the acutely cocaine-intoxicated patient sustaining maxillofacial trauma: report of a case and review of the literature. *J Oral Maxillofac Surg* 2003 Aug;61(8):964–967. [PubMed: 12905452]
81. Goodger NM, Wang J, Pogrel MA. Palatal and nasal necrosis resulting from cocaine misuse. *Br Dent J* 2005 Mar 26;198(6):333–334. [PubMed: 15789087]
82. Kuczkowski KM. The effects of drug abuse on pregnancy. *Curr Opin Obstet Gynecol* 2007 Dec;19(6):578–585. [PubMed: 18007137]
83. Phupong V, Darojn D. Amphetamine abuse in pregnancy: the impact on obstetric outcome. *Arch Gynecol Obstet* 2007 Aug;276(2):167–170. [PubMed: 17285340]
84. Williams JH, Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. *Eur Child Adolesc Psychiatry* 2007 Jun;16(4):243–253. [PubMed: 17200791]
85. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. *Eur J Neurol* 2000 Nov;7(6):595–606. [PubMed: 11136345]
86. Warner EA. Cocaine abuse. *Ann Intern Med* 1993 Aug 1;119(3):226–235. [PubMed: 8323092]
87. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. *Am J Addict* 2000 Winter;9(1):28–37. [PubMed: 10914291]
88. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2007 Nov 15;31(8):1556–1571. [PubMed: 17884274]
89. Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine. *Am J Psychiatry* 1999 Apr;156(4):662. [PubMed: 10200757]
90. Mello NK, Mendelson JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. *Pharmacol Biochem Behav* 1997 Jul;57(3):571–599. [PubMed: 9218281]
91. Carey JC. Pharmacological effects on sexual function. *Obstet Gynecol Clin North Am* 2006 Dec;33(4):599–620. [PubMed: 17116504]
92. Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. *Am J Cardiol* 2007 Sep 15;100(6):1040–1043. [PubMed: 17826394]
93. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. *N Engl J Med* 2001 Aug 2;345(5):351–358. [PubMed: 11484693]
94. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. *Am J Med* 2007 Feb;120(2):165–171. [PubMed: 17275458]
95. Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. *Curr Opin Pulm Med* 2001 Mar;7(2):43–61. [PubMed: 11224724]
96. Wolff AJ, O'Donnell AE. Pulmonary effects of illicit drug use. *Clin Chest Med* 2004 Mar;25(1):203–216. [PubMed: 15062611]

97. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. *Top HIV Med* 2006 Jun–Jul;14(2):84–87. [PubMed: 16835463]
98. Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. *AIDS* 1987 Jul;1(2):67–76. [PubMed: 3130084]
99. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. *JAMA* 1989 Jan 27;261(4):561–565. [PubMed: 2909798]
100. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. *J Infect Dis* 2002 Dec 1;186(11):1558–1564. [PubMed: 12447730]
101. Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. *Am J Public Health* 1993 Aug;83(8):1144–1148. [PubMed: 8342724]
102. Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. *N Engl J Med* 1994 Nov 24;331(21):1422–1427. [PubMed: 7969281]
103. Fisher DG, Reynolds GL, Napper LE. Use of crystal methamphetamine, Viagra, and sexual behavior. *Curr Opin Infect Dis* Feb;23(1):53–56. [PubMed: 19918176]
104. Stall R, Paul JP, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men's Health Study. *Addiction* 2001 Nov;96(11):1589–1601. [PubMed: 11784456]
105. Colfax G, Coates TJ, Husnik MJ, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. *J Urban Health* 2005 Mar;82(1 Suppl 1):i62–i70. [PubMed: 15738319]
106. Halkitis PN, Mukherjee PP, Palamar JJ. Longitudinal modeling of methamphetamine use and sexual risk behaviors in gay and bisexual men. *AIDS Behav* 2009 Aug;13(4):783–791. [PubMed: 18661225]
107. Thiede H, Jenkins RA, Carey JW, et al. Determinants of recent HIV infection among Seattle-area men who have sex with men. *Am J Public Health* 2009 Apr;99 Suppl 1:S157–S164. [PubMed: 18445808]
108. Semple SJ, Strathdee SA, Zians J, Patterson TL. Sexual risk behavior associated with co-administration of methamphetamine and other drugs in a sample of HIV-positive men who have sex with men. *Am J Addict* 2009 Jan–Feb;18(1):65–72. [PubMed: 19219667]
109. Prestage G, Jin F, Kippax S, Zablotska I, Imrie J, Grulich A. Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. *J Sex Med* 2009 Aug;6(8):2311–2320. [PubMed: 19493293]
110. Sanchez TH, Gallagher KM. Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. *J Acquir Immune Defic Syndr* 2006 May;42(1):95–100. [PubMed: 16763497]
111. Ostrow DG, Plankey MW, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. *J Acquir Immune Defic Syndr* 2009 Jul 1;51(3):349–355. [PubMed: 19387357]
112. Force USPST. Screening for Illicit Drug Use: U.S. Preventive Services Task Force Recommendation Statement. AHRQ Publication No. No. 08-05108-EF-3. [http://www.ahrq.gov/clinic/uspstf08/druguse/drugrs.htm]
113. Kulig JW. Tobacco, alcohol, and other drugs: the role of the pediatrician in prevention, identification, and management of substance abuse. *Pediatrics* 2005 Mar;115(3):816–821. [PubMed: 15741395]
114. Gynecology. Guidelines for Women's Health Care. 2nd edition ed.. Washington, D.C.: 2002. ACoOa.
115. Sullivan, E.; Fleming, M. Co-Chairs CP. Center for Substance Abuse Treatment SAaMHSA, ed. Rockville, MD: U.S. Department of Health and Human Services; 1997. A Guide to Substance Abuse Services for Primary Care Clinicians: Treatment Improvement Protocol (TIP) Series 24.

116. Zgierska, A.; Fleming, MF. Screening and Brief Intervention. In: Ries, RK.; Fiellin, DA.; Miller, SC.; Saitz, R., editors. *Principles of Addiction Medicine*. Fourth Edition ed. Wolters Kluwer Lippincott Williams and Wilkins; 2009.
117. Barry, KL. Center for Substance Abuse Treatment SAAmHSA, ed. Rockville, MD: U.S. Department of Health and Human Services; 1999. *Brief Interventions and Brief Therapies for Substance Abuse: Treatment Improvement Protocol (TIP) Series 34*.
118. Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. *Arch Intern Med* 2005 May 9;165(9):986–995. [PubMed: 15883236]
119. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. *Cochrane Database Syst Rev*. 2007;(2) CD004148.
120. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2004 Apr 6;140(7):557–568. [PubMed: 15068985]
121. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. *Drug Alcohol Depend* 2009 Jan 1;99(1–3):280–295. [PubMed: 18929451]
122. Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. *Drug Alcohol Depend* 2005 Jan 7;77(1):49–59. [PubMed: 15607841]
123. Baker A, Lee NK, Claire M, et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. *Addiction* 2005 Mar;100(3):367–378. [PubMed: 15733250]
124. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. *Curr Opin Psychiatry* 2009 May;22(3):263–268. [PubMed: 19307968]
125. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. *Am J Psychiatry* 2008 Feb;165(2):179–187. [PubMed: 18198270]
126. Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. *Addiction* 1998 May;93(5):713–727. [PubMed: 9692270]
127. Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. *J Consult Clin Psychol* 1998 Oct;66(5):832–837. [PubMed: 9803702]
128. Monti PM, Rohsenow DJ, Michalec E, Martin RA, Abrams DB. Brief coping skills treatment for cocaine abuse: substance use outcomes at three months. *Addiction* 1997 Dec;92(12):1717–1728. [PubMed: 9581004]
129. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. *Am J Drug Alcohol Abuse* Sep 1991;17(3):229–247. [PubMed: 1928019]
130. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. *Drug Alcohol Rev* 2008 May;27(3):309–317. [PubMed: 18368613]
131. Higgins, ST.; Tidey, JW.; Rogers, RE. Contingency Management and the Community Reinforcement Approach. In: Ries, RK.; Fiellin, DA.; Miller, SC.; Saitz, R., editors. *Principles of Addiction Medicine*. Fourth Edition ed. Wolters Kluwer Lippincott Williams and Wilkins; 2009.
132. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. *Drug Alcohol Depend* 2000 Feb 1;58(1–2):55–66. [PubMed: 10669055]

133. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. *Addiction* 2006 Feb;101(2):192–203. [PubMed: 16445548]
134. Prendergast ML, Podus D, Chang E, Urada D. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. *Drug Alcohol Depend* 2002 Jun 1;67(1):53–72. [PubMed: 12062779]
135. Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. *Psychol Addict Behav* 2003 Mar;17(1):73–82. [PubMed: 12665084]
136. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. *J Consult Clin Psychol* 2000 Feb;68(1):64–72. [PubMed: 10710841]
137. Petry NM, Alessi SM, Hanson T. Contingency management improves abstinence and quality of life in cocaine abusers. *J Consult Clin Psychol* 2007 Apr;75(2):307–315. [PubMed: 17469888]
138. Secades-Villa R, Garcia-Rodriguez O, Higgins ST, Fernandez-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. *J Subst Abuse Treat* 2008 Mar;34(2):202–207. [PubMed: 17512158]
139. Rawson RA, McCann MJ, Flammio F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. *Addiction* 2006 Feb;101(2):267–274. [PubMed: 16445555]
140. Roll JM, Petry NM, Stitzer ML, et al. Contingency management for the treatment of methamphetamine use disorders. *Am J Psychiatry* 2006 Nov;163(11):1993–1999. [PubMed: 17074952]
141. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. *Drug Alcohol Depend* 2005 May 9;78(2):125–134. [PubMed: 15845315]
142. Lima MS, Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. *Cochrane Database Syst Rev*. 2003;(2) CD002950.
143. Elkashef A, Holmes TH, Bloch DA, et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. *Addiction* 2005 Mar;100 Suppl 1:91–101. [PubMed: 15730353]
144. Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. *Am J Drug Alcohol Abuse* 2007;33(3):367–378. [PubMed: 17613964]
145. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. *Arch Gen Psychiatry* 2006 Feb;63(2):219–228. [PubMed: 16461866]

Table 1

Medical complications of stimulant use

Organ system	Acute complications	Chronic complications
Central nervous system	Hallucinations, esp. tactile	Psychotic symptoms
	Dyskinesia	Cerebrovascular disease/stroke
	Seizures	Movement disorders, e.g., dystonic reactions, akathisia, choreoathetosis, tardive dyskinesia
Cardiovascular system	Tachycardia	Myocarditis
	Hypertension	Cardiomyopathy
	Myocardial infarction	Myocardial fibrosis
	Arrhythmias	Myocardial infarction
Pulmonary	Cough, shortness of breath, wheezing	Interstitial pneumonitis
	Pulmonary edema, hemorrhage	Bronchiolitis obliterans
	Pneumothorax	
Renal		Renal ischemia
		Renal failure
Gastrointestinal	Reduced gastric motility	Gastric ulceration and perforation
		Intestinal infarction
		Ischemic colitis
Liver		Viral hepatitis secondary to contaminated syringe use
Endocrine	Reduced prolactin	Inc, normal or dec. prolactin
	Increased epinephrine, CRH, ACTH, cortisol and luteinizing hormones	Normal testosterone, cortisol, LH, thyroid hormones
Musculoskeletal	Movement disorders (see CNS)	Rhabdomyolysis
Head and neck	Rhinitis	Rhinitis
		Perforated nasal septum
		Nasal and gingival ulceration
		Sinusitis
		Dental decay and periodontal disease
		Xerostomia
		Corneal ulcers
		Vasculitis syndromes
		Erectile dysfunction
		Irregular menses
Reproductive	Vaginal bleeding	FDA category C
	Abruption placenta	Placenta previa
	Premature rupture of membranes	Low birth weight
General/other	Dehydration	Weight loss
		Nutritional deficits